Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.
作者信息
Bruce Ian N, Golam Sarowar, Steenkamp Jason, Wang Pearl, Worthington Evelyn, Desta Barnabas, Psachoulia Konstantina, Erhardt Wilma, Tummala Raj
机构信息
Division of Musculoskeletal & Dermatological Sciences, Centre for Epidemiology Versus Arthritis, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Global Market Access & Pricing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
出版信息
J Comp Eff Res. 2023 Jan;12(1):e220192. doi: 10.2217/cer-2022-0192. Epub 2022 Dec 14.
Abstract
摘要
相似文献
1
Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.回复信：阿尼鲁单抗与贝利尤单抗治疗成人系统性红斑狼疮疗效的间接治疗比较
J Comp Eff Res. 2023 Jan;12(1):e220192. doi: 10.2217/cer-2022-0192. Epub 2022 Dec 14.
2
Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.致编辑的信：阿尼鲁单抗与贝利尤单抗治疗成年系统性红斑狼疮疗效的间接治疗比较
J Comp Eff Res. 2023 Jan;12(1):e220106. doi: 10.2217/cer-2022-0106. Epub 2022 Dec 14.
3
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.阿尼鲁单抗与贝利尤单抗治疗成人系统性红斑狼疮疗效的间接比较。
J Comp Eff Res. 2022 Jul;11(10):765-777. doi: 10.2217/cer-2022-0040. Epub 2022 May 12.
4
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks.贝利尤单抗与阿尼鲁单抗治疗成人系统性红斑狼疮：52 周临床应答的间接比较。
Lupus Sci Med. 2023 May;10(1). doi: 10.1136/lupus-2023-000907.
5
Successful treatment of systemic lupus erythematosus with residual disease activity by switching from belimumab to anifrolumab.
Mod Rheumatol. 2024 Oct 15;34(6):1281-1283. doi: 10.1093/mr/roae038.
6
Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus.阿尼氟单抗治疗难治性皮肤红斑狼疮的快速疗效
J Am Acad Dermatol. 2023 Jul;89(1):171-173. doi: 10.1016/j.jaad.2023.02.044. Epub 2023 Mar 5.
7
An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.贝利尤单抗静脉注射与皮下注射治疗系统性红斑狼疮高疾病活动度患者疗效的间接比较。
J Comp Eff Res. 2018 Jun;7(6):581-593. doi: 10.2217/cer-2017-0085. Epub 2018 Apr 25.
8
Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates.阿联酋阿巴西普单抗与贝利尤单抗相比的成本效益的微观模拟模型。
J Med Econ. 2024;27(sup1):23-34. doi: 10.1080/13696998.2024.2320603. Epub 2024 Mar 11.
9
Anifrolumab (Saphnelo) for systemic lupus erythematosus.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):146-147.
10
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.已有的器官损伤会降低贝利尤单抗在系统性红斑狼疮中的疗效。
Ann Rheum Dis. 2019 Jul;78(7):1006-1007. doi: 10.1136/annrheumdis-2018-214880. Epub 2019 Jan 4.
引用本文的文献
1
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks.贝利尤单抗与阿尼鲁单抗治疗成人系统性红斑狼疮：52 周临床应答的间接比较。
Lupus Sci Med. 2023 May;10(1). doi: 10.1136/lupus-2023-000907.
本文引用的文献
1
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.I型干扰素抑制剂阿尼鲁单抗治疗活动性系统性红斑狼疮（TULIP-1）：一项随机、对照、3期试验
Lancet Rheumatol. 2019 Dec;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1. Epub 2019 Nov 11.
2
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.阿尼鲁单抗与贝利尤单抗治疗成人系统性红斑狼疮疗效的间接比较。
J Comp Eff Res. 2022 Jul;11(10):765-777. doi: 10.2217/cer-2022-0040. Epub 2022 May 12.
3
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.依洛尤单抗的疗效和安全性与 I 型干扰素基因特征和 SLE 患者的临床亚组有关：两项 III 期临床试验汇总数据的事后分析。
Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25.
4
Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study.评估用于锚定间接比较的总体调整方法的性能：一项模拟研究。
Stat Med. 2020 Dec 30;39(30):4885-4911. doi: 10.1002/sim.8759. Epub 2020 Oct 4.
5
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.阿尼鲁单抗治疗活动性系统性红斑狼疮的试验。
N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.
6
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.皮下注射贝利尤单抗治疗红斑狼疮的疗效和安全性：一项 52 周随机、双盲、安慰剂对照研究。
Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7.
7
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.贝利尤单抗治疗系统性红斑狼疮：高疾病活动度预测应答。
Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.
8
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.一项关于贝利木单抗（一种抑制B淋巴细胞刺激因子的单克隆抗体）治疗系统性红斑狼疮患者的III期随机安慰剂对照研究。
Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.
9
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.贝利尤单抗治疗系统性红斑狼疮患者的疗效和安全性：一项随机、安慰剂对照、3 期临床试验。
Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.
10
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.2004年不列颠群岛狼疮评估组系统性红斑狼疮患者疾病活动指数更新版的制定与初步验证
Rheumatology (Oxford). 2005 Jul;44(7):902-6. doi: 10.1093/rheumatology/keh624. Epub 2005 Apr 6.
Zotero 插件